Voxilaprevir: Difference between revisions
Content deleted Content added
clean up, rmv redlink portal |
User:MB's cleanup broke the box, and also was not correct: single curly-braces are a proper character in chemical names |
||
Line 3: | Line 3: | ||
| drug_name = |
| drug_name = |
||
| type = |
| type = |
||
| IUPAC_name = (1''R'',18''R'',20''R'',24''S'',27''S'',28''S'')-''N''-[(1''R'',2''R'')-2-(Difluoromethyl)-1-<nowiki>{[(</nowiki>1-methylcyclopropyl)sulfonyl]carbamoyl |
| IUPAC_name = (1''R'',18''R'',20''R'',24''S'',27''S'',28''S'')-''N''-[(1''R'',2''R'')-2-(Difluoromethyl)-1-<nowiki>{[(</nowiki>1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0<sup>3,12</sup>.0<sup>5,10</sup>.0<sup>18,20</sup>]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide |
||
| image = Voxilaprevir.svg |
| image = Voxilaprevir.svg |
||
| alt = |
| alt = |
Revision as of 07:49, 3 August 2020
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[2]
On 18 July 2017, Vosevi was approved by Food and drug administration.[3]
References
- ^ "voxilaprevir_msds".
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C